Apple
AAPL
Taylor Morrison Home
TMHC
D.R. Horton
DHI
4
Petroleo Brasileiro SA Petrobras
PBR
5
Vale SA
VALE
US Stock MarketDetailed Quotes
BTAI BioXcel Therapeutics
- 2.310
- +0.130+5.96%
Close Mar 27 16:00 ET
- 2.250
- -0.060-2.60%
Post 19:34 ET
7.84MMarket Cap-0.07P/E (TTM)
2.370High2.120Low218.06KVolume2.290Open2.180Pre Close487.33KTurnover8.49%Turnover RatioLossP/E (Static)3.39MShares49.58452wk High-0.09P/B5.93MFloat Cap1.72052wk Low--Dividend TTM2.57MShs Float1144.000Historical High--Div YieldTTM11.47%Amplitude1.720Historical Low2.234Avg Price1Lot Size
About BioXcel Therapeutics Company
BioXcel Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of artificial intelligence solutions in neuroscience and immuno-oncology. It also focuses on utilizing technology and research to develop therapeutics solutions. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.
Company Profile
SymbolBTAI
Company NameBioXcel Therapeutics
Listing DateMar 8, 2018
Issue Price11.00
Founded2017
CEODr. Vimal Mehta, PhD
MarketNASDAQ
Employees74
Fiscal Year Ends12-31
Address555 Long Wharf Drive,12th floor
CityNew Haven
ProvinceConnecticut
CountryUnited States of America
Zip Code06511
Phone1-475-238-6837
Company Executives
- Name
- Position
- Salary
- Dr. Vimal Mehta, PhD
- Director, Chief Executive Officer and President
- 4.73M
- Richard I. Steinhart
- Senior Vice President, Chief Financial Officer and Principal Accounting Officer
- --
- Javier Rodriguez
- Senior Vice President, Chief Legal Officer and Corporate Secretary
- 1.12M
- Dr. Vincent J. O'Neill, M.D.
- Executive Vice President, Chief of Product Development and Chief Medical Officer
- --
- Dr. Frank D. Yocca, PhD
- Senior Vice President and Chief Scientific Officer
- --
- Dr. Peter Mueller,PhD
- Chairman of the Board
- 367.33K
- Dr. Rajiv Patni, M.D.
- Director
- --
- June Bray
- Independent Director
- 327.33K
- Michael Miller
- Independent Director
- 332.33K
- Dr. Sandeep Laumas, M.D.
- Independent Director
- 329.83K
- Dr. Michal Votruba, M.D.,PhD
- Independent Director
- 307.33K
- David J. Mack
- Independent Director
- --
Market Insights
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025